Leading nutritional ingredients producer DSM Nutritional Products announces that their geniVida™ Bone Blend has been shown in a clinical trial to significantly increase bone mineral density by up to 3.4% in post-menopausal women after only 6 months supplementation. This new data was presented at the IOF World Congress on Osteoporosis, Florence, Italy, May 5-8, 2010.
Due to an ageing population, bone loss and the resulting increased risk of bone fracture is a growing problem globally. Approximately a third of postmenopausal women in USA and Europe are affected.
The clinical trial, conducted in collaboration with Creighton University, Omaha, USA, took the form of a pilot, randomized, placebo-controlled, double-blind study in 58 healthy, early post-menopausal women. The geniVida™ Bone Blend is a patent protected combination of geniVida™ brand pure genistein, ROPUFA® brand omega-3 fatty acids EPA and DHA, and the vitamins Quali-D™ D3 and Quali-K™ K1.
William Black, Vice-President of New Nutritional Ingredients at DSM, says: “The new study provides evidence of the significant health benefits offered by a multi-nutrient solution to a multifactorial health issue such as bone mineral density. This new evidence complements previous data showing significant menopause symptom (hot flash) relief for post-menopausal women supplementing with geniVida™ genistein. geniVida™ therefore potentially offers solutions for unmet short-term and long-term health needs for mature women”.
About DSM Nutritional Products
DSM Nutritional Products is the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries.
The business has sales of over EUR 2 billion and a long tradition as a pioneer in the discovery of new products, new formulations and attractive applications for all industry segments. More information at www.dsmnutritionalproducts.com and www.qualityforlife.com
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance.
Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM manages its business with a focus on the triple bottom line of economic prosperity, environmental quality and social equity, which it pursues simultaneously and in parallel. DSM has annual net sales of about €8 billion and employs some 22,700 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com